Changes in quality of life and disease-related symptoms in patients with polycythemia vera receiving ruxolitinib or standard therapy.
Identifieur interne : 001B58 ( PubMed/Corpus ); précédent : 001B57; suivant : 001B59Changes in quality of life and disease-related symptoms in patients with polycythemia vera receiving ruxolitinib or standard therapy.
Auteurs : Ruben Mesa ; Srdan Verstovsek ; Jean-Jacques Kiladjian ; Martin Griesshammer ; Tamas Masszi ; Simon Durrant ; Francesco Passamonti ; Claire N. Harrison ; Fabrizio Pane ; Pierre Zachee ; Huiling Zhen ; Mark M. Jones ; Shreekant Parasuraman ; Jingjin Li ; Isabelle Côté ; Dany Habr ; Alessandro M. VannucchiSource :
- European journal of haematology [ 1600-0609 ] ; 2016.
English descriptors
- KwdEn :
- Adult, Aged, Female, Humans, Male, Middle Aged, Patient Reported Outcome Measures, Polycythemia Vera (diagnosis), Polycythemia Vera (epidemiology), Polycythemia Vera (therapy), Protein Kinase Inhibitors (administration & dosage), Protein Kinase Inhibitors (adverse effects), Protein Kinase Inhibitors (therapeutic use), Pyrazoles (administration & dosage), Pyrazoles (adverse effects), Pyrazoles (therapeutic use), Quality of Life, Standard of Care, Treatment Outcome.
- MESH :
- chemical , administration & dosage : Protein Kinase Inhibitors, Pyrazoles.
- chemical , adverse effects : Protein Kinase Inhibitors, Pyrazoles.
- diagnosis : Polycythemia Vera.
- epidemiology : Polycythemia Vera.
- chemical , therapeutic use : Protein Kinase Inhibitors, Pyrazoles.
- therapy : Polycythemia Vera.
- Adult, Aged, Female, Humans, Male, Middle Aged, Patient Reported Outcome Measures, Quality of Life, Standard of Care, Treatment Outcome.
Abstract
Polycythemia vera (PV)-related symptoms may not be adequately controlled with conventional therapy. This current analysis of the RESPONSE trial evaluated the effects of ruxolitinib compared with standard therapy on quality of life (QoL) and symptoms in patients with PV who were hydroxyurea resistant/intolerant.
DOI: 10.1111/ejh.12707
PubMed: 26608702
Links to Exploration step
pubmed:26608702Le document en format XML
<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en">Changes in quality of life and disease-related symptoms in patients with polycythemia vera receiving ruxolitinib or standard therapy.</title><author><name sortKey="Mesa, Ruben" sort="Mesa, Ruben" uniqKey="Mesa R" first="Ruben" last="Mesa">Ruben Mesa</name><affiliation><nlm:affiliation>Mayo Clinic Cancer Center, Scottsdale, AZ, USA.</nlm:affiliation></affiliation></author><author><name sortKey="Verstovsek, Srdan" sort="Verstovsek, Srdan" uniqKey="Verstovsek S" first="Srdan" last="Verstovsek">Srdan Verstovsek</name><affiliation><nlm:affiliation>The University of Texas MD Anderson Cancer Center, Houston, TX, USA.</nlm:affiliation></affiliation></author><author><name sortKey="Kiladjian, Jean Jacques" sort="Kiladjian, Jean Jacques" uniqKey="Kiladjian J" first="Jean-Jacques" last="Kiladjian">Jean-Jacques Kiladjian</name><affiliation><nlm:affiliation>Hôpital Saint-Louis et Université Paris Diderot, Paris, France.</nlm:affiliation></affiliation></author><author><name sortKey="Griesshammer, Martin" sort="Griesshammer, Martin" uniqKey="Griesshammer M" first="Martin" last="Griesshammer">Martin Griesshammer</name><affiliation><nlm:affiliation>Johannes Wesling Clinic, Minden, Germany.</nlm:affiliation></affiliation></author><author><name sortKey="Masszi, Tamas" sort="Masszi, Tamas" uniqKey="Masszi T" first="Tamas" last="Masszi">Tamas Masszi</name><affiliation><nlm:affiliation>St. István and St. László Hospital, Budapest, Hungary.</nlm:affiliation></affiliation></author><author><name sortKey="Durrant, Simon" sort="Durrant, Simon" uniqKey="Durrant S" first="Simon" last="Durrant">Simon Durrant</name><affiliation><nlm:affiliation>Royal Brisbane & Women's Hospital, Brisbane, Qld, Australia.</nlm:affiliation></affiliation></author><author><name sortKey="Passamonti, Francesco" sort="Passamonti, Francesco" uniqKey="Passamonti F" first="Francesco" last="Passamonti">Francesco Passamonti</name><affiliation><nlm:affiliation>Ospedale di Circolo e Fondazione Macchi, Varese, Italy.</nlm:affiliation></affiliation></author><author><name sortKey="Harrison, Claire N" sort="Harrison, Claire N" uniqKey="Harrison C" first="Claire N" last="Harrison">Claire N. Harrison</name><affiliation><nlm:affiliation>Guy's and St. Thomas' NHS Foundation Trust, London, UK.</nlm:affiliation></affiliation></author><author><name sortKey="Pane, Fabrizio" sort="Pane, Fabrizio" uniqKey="Pane F" first="Fabrizio" last="Pane">Fabrizio Pane</name><affiliation><nlm:affiliation>University of Naples Federico II, Naples, Italy.</nlm:affiliation></affiliation></author><author><name sortKey="Zachee, Pierre" sort="Zachee, Pierre" uniqKey="Zachee P" first="Pierre" last="Zachee">Pierre Zachee</name><affiliation><nlm:affiliation>ZNA Stuivenberg, Antwerp, Belgium.</nlm:affiliation></affiliation></author><author><name sortKey="Zhen, Huiling" sort="Zhen, Huiling" uniqKey="Zhen H" first="Huiling" last="Zhen">Huiling Zhen</name><affiliation><nlm:affiliation>Incyte Corporation, Wilmington, DE, USA.</nlm:affiliation></affiliation></author><author><name sortKey="Jones, Mark M" sort="Jones, Mark M" uniqKey="Jones M" first="Mark M" last="Jones">Mark M. Jones</name><affiliation><nlm:affiliation>Incyte Corporation, Wilmington, DE, USA.</nlm:affiliation></affiliation></author><author><name sortKey="Parasuraman, Shreekant" sort="Parasuraman, Shreekant" uniqKey="Parasuraman S" first="Shreekant" last="Parasuraman">Shreekant Parasuraman</name><affiliation><nlm:affiliation>Incyte Corporation, Wilmington, DE, USA.</nlm:affiliation></affiliation></author><author><name sortKey="Li, Jingjin" sort="Li, Jingjin" uniqKey="Li J" first="Jingjin" last="Li">Jingjin Li</name><affiliation><nlm:affiliation>Novartis Pharmaceuticals Corporation, East Hanover, NJ, USA.</nlm:affiliation></affiliation></author><author><name sortKey="Cote, Isabelle" sort="Cote, Isabelle" uniqKey="Cote I" first="Isabelle" last="Côté">Isabelle Côté</name><affiliation><nlm:affiliation>Novartis Pharmaceuticals Corporation, East Hanover, NJ, USA.</nlm:affiliation></affiliation></author><author><name sortKey="Habr, Dany" sort="Habr, Dany" uniqKey="Habr D" first="Dany" last="Habr">Dany Habr</name><affiliation><nlm:affiliation>Novartis Pharmaceuticals Corporation, East Hanover, NJ, USA.</nlm:affiliation></affiliation></author><author><name sortKey="Vannucchi, Alessandro M" sort="Vannucchi, Alessandro M" uniqKey="Vannucchi A" first="Alessandro M" last="Vannucchi">Alessandro M. Vannucchi</name><affiliation><nlm:affiliation>University of Florence, Florence, Italy.</nlm:affiliation></affiliation></author></titleStmt><publicationStmt><idno type="wicri:source">PubMed</idno><date when="2016">2016</date><idno type="RBID">pubmed:26608702</idno><idno type="pmid">26608702</idno><idno type="doi">10.1111/ejh.12707</idno><idno type="wicri:Area/PubMed/Corpus">001B58</idno><idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Corpus" wicri:corpus="PubMed">001B58</idno></publicationStmt><sourceDesc><biblStruct><analytic><title xml:lang="en">Changes in quality of life and disease-related symptoms in patients with polycythemia vera receiving ruxolitinib or standard therapy.</title><author><name sortKey="Mesa, Ruben" sort="Mesa, Ruben" uniqKey="Mesa R" first="Ruben" last="Mesa">Ruben Mesa</name><affiliation><nlm:affiliation>Mayo Clinic Cancer Center, Scottsdale, AZ, USA.</nlm:affiliation></affiliation></author><author><name sortKey="Verstovsek, Srdan" sort="Verstovsek, Srdan" uniqKey="Verstovsek S" first="Srdan" last="Verstovsek">Srdan Verstovsek</name><affiliation><nlm:affiliation>The University of Texas MD Anderson Cancer Center, Houston, TX, USA.</nlm:affiliation></affiliation></author><author><name sortKey="Kiladjian, Jean Jacques" sort="Kiladjian, Jean Jacques" uniqKey="Kiladjian J" first="Jean-Jacques" last="Kiladjian">Jean-Jacques Kiladjian</name><affiliation><nlm:affiliation>Hôpital Saint-Louis et Université Paris Diderot, Paris, France.</nlm:affiliation></affiliation></author><author><name sortKey="Griesshammer, Martin" sort="Griesshammer, Martin" uniqKey="Griesshammer M" first="Martin" last="Griesshammer">Martin Griesshammer</name><affiliation><nlm:affiliation>Johannes Wesling Clinic, Minden, Germany.</nlm:affiliation></affiliation></author><author><name sortKey="Masszi, Tamas" sort="Masszi, Tamas" uniqKey="Masszi T" first="Tamas" last="Masszi">Tamas Masszi</name><affiliation><nlm:affiliation>St. István and St. László Hospital, Budapest, Hungary.</nlm:affiliation></affiliation></author><author><name sortKey="Durrant, Simon" sort="Durrant, Simon" uniqKey="Durrant S" first="Simon" last="Durrant">Simon Durrant</name><affiliation><nlm:affiliation>Royal Brisbane & Women's Hospital, Brisbane, Qld, Australia.</nlm:affiliation></affiliation></author><author><name sortKey="Passamonti, Francesco" sort="Passamonti, Francesco" uniqKey="Passamonti F" first="Francesco" last="Passamonti">Francesco Passamonti</name><affiliation><nlm:affiliation>Ospedale di Circolo e Fondazione Macchi, Varese, Italy.</nlm:affiliation></affiliation></author><author><name sortKey="Harrison, Claire N" sort="Harrison, Claire N" uniqKey="Harrison C" first="Claire N" last="Harrison">Claire N. Harrison</name><affiliation><nlm:affiliation>Guy's and St. Thomas' NHS Foundation Trust, London, UK.</nlm:affiliation></affiliation></author><author><name sortKey="Pane, Fabrizio" sort="Pane, Fabrizio" uniqKey="Pane F" first="Fabrizio" last="Pane">Fabrizio Pane</name><affiliation><nlm:affiliation>University of Naples Federico II, Naples, Italy.</nlm:affiliation></affiliation></author><author><name sortKey="Zachee, Pierre" sort="Zachee, Pierre" uniqKey="Zachee P" first="Pierre" last="Zachee">Pierre Zachee</name><affiliation><nlm:affiliation>ZNA Stuivenberg, Antwerp, Belgium.</nlm:affiliation></affiliation></author><author><name sortKey="Zhen, Huiling" sort="Zhen, Huiling" uniqKey="Zhen H" first="Huiling" last="Zhen">Huiling Zhen</name><affiliation><nlm:affiliation>Incyte Corporation, Wilmington, DE, USA.</nlm:affiliation></affiliation></author><author><name sortKey="Jones, Mark M" sort="Jones, Mark M" uniqKey="Jones M" first="Mark M" last="Jones">Mark M. Jones</name><affiliation><nlm:affiliation>Incyte Corporation, Wilmington, DE, USA.</nlm:affiliation></affiliation></author><author><name sortKey="Parasuraman, Shreekant" sort="Parasuraman, Shreekant" uniqKey="Parasuraman S" first="Shreekant" last="Parasuraman">Shreekant Parasuraman</name><affiliation><nlm:affiliation>Incyte Corporation, Wilmington, DE, USA.</nlm:affiliation></affiliation></author><author><name sortKey="Li, Jingjin" sort="Li, Jingjin" uniqKey="Li J" first="Jingjin" last="Li">Jingjin Li</name><affiliation><nlm:affiliation>Novartis Pharmaceuticals Corporation, East Hanover, NJ, USA.</nlm:affiliation></affiliation></author><author><name sortKey="Cote, Isabelle" sort="Cote, Isabelle" uniqKey="Cote I" first="Isabelle" last="Côté">Isabelle Côté</name><affiliation><nlm:affiliation>Novartis Pharmaceuticals Corporation, East Hanover, NJ, USA.</nlm:affiliation></affiliation></author><author><name sortKey="Habr, Dany" sort="Habr, Dany" uniqKey="Habr D" first="Dany" last="Habr">Dany Habr</name><affiliation><nlm:affiliation>Novartis Pharmaceuticals Corporation, East Hanover, NJ, USA.</nlm:affiliation></affiliation></author><author><name sortKey="Vannucchi, Alessandro M" sort="Vannucchi, Alessandro M" uniqKey="Vannucchi A" first="Alessandro M" last="Vannucchi">Alessandro M. Vannucchi</name><affiliation><nlm:affiliation>University of Florence, Florence, Italy.</nlm:affiliation></affiliation></author></analytic><series><title level="j">European journal of haematology</title><idno type="eISSN">1600-0609</idno><imprint><date when="2016" type="published">2016</date></imprint></series></biblStruct></sourceDesc></fileDesc><profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Adult</term><term>Aged</term><term>Female</term><term>Humans</term><term>Male</term><term>Middle Aged</term><term>Patient Reported Outcome Measures</term><term>Polycythemia Vera (diagnosis)</term><term>Polycythemia Vera (epidemiology)</term><term>Polycythemia Vera (therapy)</term><term>Protein Kinase Inhibitors (administration & dosage)</term><term>Protein Kinase Inhibitors (adverse effects)</term><term>Protein Kinase Inhibitors (therapeutic use)</term><term>Pyrazoles (administration & dosage)</term><term>Pyrazoles (adverse effects)</term><term>Pyrazoles (therapeutic use)</term><term>Quality of Life</term><term>Standard of Care</term><term>Treatment Outcome</term></keywords><keywords scheme="MESH" type="chemical" qualifier="administration & dosage" xml:lang="en"><term>Protein Kinase Inhibitors</term><term>Pyrazoles</term></keywords><keywords scheme="MESH" type="chemical" qualifier="adverse effects" xml:lang="en"><term>Protein Kinase Inhibitors</term><term>Pyrazoles</term></keywords><keywords scheme="MESH" qualifier="diagnosis" xml:lang="en"><term>Polycythemia Vera</term></keywords><keywords scheme="MESH" qualifier="epidemiology" xml:lang="en"><term>Polycythemia Vera</term></keywords><keywords scheme="MESH" type="chemical" qualifier="therapeutic use" xml:lang="en"><term>Protein Kinase Inhibitors</term><term>Pyrazoles</term></keywords><keywords scheme="MESH" qualifier="therapy" xml:lang="en"><term>Polycythemia Vera</term></keywords><keywords scheme="MESH" xml:lang="en"><term>Adult</term><term>Aged</term><term>Female</term><term>Humans</term><term>Male</term><term>Middle Aged</term><term>Patient Reported Outcome Measures</term><term>Quality of Life</term><term>Standard of Care</term><term>Treatment Outcome</term></keywords></textClass></profileDesc></teiHeader><front><div type="abstract" xml:lang="en">Polycythemia vera (PV)-related symptoms may not be adequately controlled with conventional therapy. This current analysis of the RESPONSE trial evaluated the effects of ruxolitinib compared with standard therapy on quality of life (QoL) and symptoms in patients with PV who were hydroxyurea resistant/intolerant.</div></front></TEI><pubmed><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">26608702</PMID><DateCreated><Year>2016</Year><Month>07</Month><Day>06</Day></DateCreated><DateCompleted><Year>2017</Year><Month>02</Month><Day>06</Day></DateCompleted><DateRevised><Year>2017</Year><Month>09</Month><Day>30</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1600-0609</ISSN><JournalIssue CitedMedium="Internet"><Volume>97</Volume><Issue>2</Issue><PubDate><Year>2016</Year><Month>Aug</Month></PubDate></JournalIssue><Title>European journal of haematology</Title><ISOAbbreviation>Eur. J. Haematol.</ISOAbbreviation></Journal><ArticleTitle>Changes in quality of life and disease-related symptoms in patients with polycythemia vera receiving ruxolitinib or standard therapy.</ArticleTitle><Pagination><MedlinePgn>192-200</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1111/ejh.12707</ELocationID><Abstract><AbstractText Label="OBJECTIVES" NlmCategory="OBJECTIVE">Polycythemia vera (PV)-related symptoms may not be adequately controlled with conventional therapy. This current analysis of the RESPONSE trial evaluated the effects of ruxolitinib compared with standard therapy on quality of life (QoL) and symptoms in patients with PV who were hydroxyurea resistant/intolerant.</AbstractText><AbstractText Label="METHODS" NlmCategory="METHODS">In the previously reported primary analysis, ruxolitinib achieved the primary composite endpoint of hematocrit control and ≥35% reduction in spleen volume at Week 32. The current analysis evaluated patient-reported outcomes using the European Organisation for Research and Treatment of Cancer Quality of Life Questionnaire-Core 30 (EORTC QLQ-C30), the Myeloproliferative Neoplasm Symptom Assessment Form (MPN-SAF), the Pruritus Symptom Impact Scale (PSIS), and the Patient Global Impression of Change (PGIC).</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">Compared with standard therapy, ruxolitinib was associated with greater improvements in global health status/QoL, functional subscales, and individual symptom scores of the EORTC QLQ-C30. At Week 32, more patients in the ruxolitinib arm (44%) achieved a ≥10-point improvement in global health status/QoL vs. standard therapy (9%). Improvements in MPN-SAF symptom scores were consistent with improvements in EORTC QLQ-C30, PSIS, and PGIC scores.</AbstractText><AbstractText Label="CONCLUSIONS" NlmCategory="CONCLUSIONS">Ruxolitinib provides clinically relevant improvements in QoL and ameliorates symptom burden in patients with PV who are hydroxyurea resistant/intolerant.</AbstractText><CopyrightInformation>© 2016 The Authors. European Journal of Haematology Published by John Wiley & Sons Ltd.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Mesa</LastName><ForeName>Ruben</ForeName><Initials>R</Initials><AffiliationInfo><Affiliation>Mayo Clinic Cancer Center, Scottsdale, AZ, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Verstovsek</LastName><ForeName>Srdan</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>The University of Texas MD Anderson Cancer Center, Houston, TX, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kiladjian</LastName><ForeName>Jean-Jacques</ForeName><Initials>JJ</Initials><AffiliationInfo><Affiliation>Hôpital Saint-Louis et Université Paris Diderot, Paris, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Griesshammer</LastName><ForeName>Martin</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Johannes Wesling Clinic, Minden, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Masszi</LastName><ForeName>Tamas</ForeName><Initials>T</Initials><AffiliationInfo><Affiliation>St. István and St. László Hospital, Budapest, Hungary.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Semmelweis University, Budapest, Hungary.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Durrant</LastName><ForeName>Simon</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Royal Brisbane & Women's Hospital, Brisbane, Qld, Australia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Passamonti</LastName><ForeName>Francesco</ForeName><Initials>F</Initials><AffiliationInfo><Affiliation>Ospedale di Circolo e Fondazione Macchi, Varese, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Harrison</LastName><ForeName>Claire N</ForeName><Initials>CN</Initials><AffiliationInfo><Affiliation>Guy's and St. Thomas' NHS Foundation Trust, London, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Pane</LastName><ForeName>Fabrizio</ForeName><Initials>F</Initials><AffiliationInfo><Affiliation>University of Naples Federico II, Naples, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Zachee</LastName><ForeName>Pierre</ForeName><Initials>P</Initials><AffiliationInfo><Affiliation>ZNA Stuivenberg, Antwerp, Belgium.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Zhen</LastName><ForeName>Huiling</ForeName><Initials>H</Initials><AffiliationInfo><Affiliation>Incyte Corporation, Wilmington, DE, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Jones</LastName><ForeName>Mark M</ForeName><Initials>MM</Initials><AffiliationInfo><Affiliation>Incyte Corporation, Wilmington, DE, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Parasuraman</LastName><ForeName>Shreekant</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Incyte Corporation, Wilmington, DE, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Li</LastName><ForeName>Jingjin</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Novartis Pharmaceuticals Corporation, East Hanover, NJ, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Côté</LastName><ForeName>Isabelle</ForeName><Initials>I</Initials><AffiliationInfo><Affiliation>Novartis Pharmaceuticals Corporation, East Hanover, NJ, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Habr</LastName><ForeName>Dany</ForeName><Initials>D</Initials><AffiliationInfo><Affiliation>Novartis Pharmaceuticals Corporation, East Hanover, NJ, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Vannucchi</LastName><ForeName>Alessandro M</ForeName><Initials>AM</Initials><AffiliationInfo><Affiliation>University of Florence, Florence, Italy.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D017428">Clinical Trial, Phase III</PublicationType><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D016448">Multicenter Study</PublicationType><PublicationType UI="D016449">Randomized Controlled Trial</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2016</Year><Month>01</Month><Day>03</Day></ArticleDate></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>Eur J Haematol</MedlineTA><NlmUniqueID>8703985</NlmUniqueID><ISSNLinking>0902-4441</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="C540383">INCB018424</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D047428">Protein Kinase Inhibitors</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D011720">Pyrazoles</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000071066" MajorTopicYN="N">Patient Reported Outcome Measures</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011087" MajorTopicYN="N">Polycythemia Vera</DescriptorName><QualifierName UI="Q000175" MajorTopicYN="N">diagnosis</QualifierName><QualifierName UI="Q000453" MajorTopicYN="Y">epidemiology</QualifierName><QualifierName UI="Q000628" MajorTopicYN="Y">therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D047428" MajorTopicYN="N">Protein Kinase Inhibitors</DescriptorName><QualifierName UI="Q000008" MajorTopicYN="N">administration & dosage</QualifierName><QualifierName UI="Q000009" MajorTopicYN="N">adverse effects</QualifierName><QualifierName UI="Q000627" MajorTopicYN="Y">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D011720" MajorTopicYN="N">Pyrazoles</DescriptorName><QualifierName UI="Q000008" MajorTopicYN="N">administration & dosage</QualifierName><QualifierName UI="Q000009" MajorTopicYN="N">adverse effects</QualifierName><QualifierName UI="Q000627" MajorTopicYN="Y">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D011788" MajorTopicYN="Y">Quality of Life</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D059039" MajorTopicYN="Y">Standard of Care</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D016896" MajorTopicYN="N">Treatment Outcome</DescriptorName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">polycythemia vera</Keyword><Keyword MajorTopicYN="N">quality of life</Keyword><Keyword MajorTopicYN="N">signs and symptoms</Keyword></KeywordList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="accepted"><Year>2015</Year><Month>11</Month><Day>18</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2015</Year><Month>11</Month><Day>27</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2015</Year><Month>11</Month><Day>27</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2017</Year><Month>2</Month><Day>7</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">26608702</ArticleId><ArticleId IdType="doi">10.1111/ejh.12707</ArticleId></ArticleIdList></PubmedData></pubmed></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Wicri/Asie/explor/AustralieFrV1/Data/PubMed/Corpus
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 001B58 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/PubMed/Corpus/biblio.hfd -nk 001B58 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Wicri/Asie
|area= AustralieFrV1
|flux= PubMed
|étape= Corpus
|type= RBID
|clé= pubmed:26608702
|texte= Changes in quality of life and disease-related symptoms in patients with polycythemia vera receiving ruxolitinib or standard therapy.
}}
Pour générer des pages wiki
HfdIndexSelect -h $EXPLOR_AREA/Data/PubMed/Corpus/RBID.i -Sk "pubmed:26608702" \
| HfdSelect -Kh $EXPLOR_AREA/Data/PubMed/Corpus/biblio.hfd \
| NlmPubMed2Wicri -a AustralieFrV1
| This area was generated with Dilib version V0.6.33. |  |